Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-37. **[Cancelled]**

Claim 38. **[Previously Presented]** A mouse monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591 or an antigen binding fragment thereof.

Claims 39-40. **[Cancelled]**

Claim 41. **[Previously Presented]** A chimeric or humanized version of the mouse monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591 or an antigen binding fragment thereof.

Claim 42. **[Cancelled]**

Claim 43. **[Previously Presented]** A hybridoma cell line 2B6, having ATCC accession number PTA-4591.

Claims 44-50. **[Cancelled]**

Claim 51. **[Withdrawn Previously Presented]** A method of treating cancer in a patient having a cancer characterized by a cancer antigen, said method comprising administering to said patient a therapeutically effective amount of a first antibody, which is a chimeric or humanized version of the mouse monoclonal antibody produced by clone 2B6, having ATCC

accession number PTA-4591, or an antigen binding fragment thereof, and a second antibody that specifically binds said cancer antigen and is cytotoxic.

Claim 52. **[Withdrawn]** The method of claim 51. wherein said cancer is breast. ovarian. prostate. cervical or pancreatic cancer.

Claim 53. **[Withdrawn]** The method of claim 51. wherein said cytotoxic antibody is Herceptin®, Rituxin®, IC14, PANOREX™, IMC-225, VITAXIN™, Campath 1H/LDP-03, LYMPHOCIDE™, or ZEVLIN™.

Claim 54. **[Withdrawn]** The method of claim 51, wherein said cancer antigen is MAGE-1, MAGE3, BAGE, GAGE-1, GAGE-2, N-acetylglucosaminyltransferase, p15, beta-catenin, MUM-1, CDK4, HER-2/neu, human papillomavirus-E6, human papillomavirus-E7, or MUC-1.

Claim 55. **[Withdrawn]** The method of claim 51. wherein said cancer antigen is a breast, ovarian, prostate. cervical, or pancreatic carcinoma antigen.

Claim 56. **[Withdrawn]** The method of claim 51 further comprising the administration of one or more additional cancer therapies.

Claim 57. **[Withdrawn]** The method of claim 56, wherein said additional cancer therapy is selected from the group consisting of chemotherapy, immunotherapy, radiation therapy, hormonal therapy. or surgery.

Claim 58. **[Withdrawn]** The method of claim 51, wherein said patient is human.

Claim 59. **[Withdrawn Previously Presented]** The method of claim 58. wherein said first antibody is a humanized version.

Claim 60. **[Withdrawn Previously Presented]** A pharmaceutical composition comprising (i) a therapeutically effective amount of a first antibody that is a chimeric or humanized version of the murine monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591, or an antigen binding fragment thereof; (ii) a second cytotoxic antibody that specifically binds a cancer antigen; and (iii) a pharmaceutically acceptable carrier.

Claim 61. **[Withdrawn Previously Presented]** The pharmaceutical composition of claim 60, wherein said first antibody is a humanized version.

Claim 62. **[Withdrawn Previously Presented]** The pharmaceutical composition of claim 60 or 61, wherein said second antibody is a human or humanized antibody.

Claim 63. **[Withdrawn]** The pharmaceutical composition of claim 60 further comprising one or more additional anti-cancer agents.

Claim 64. **[Withdrawn]** The pharmaceutical composition of claim 63, wherein said anti-cancer agent is a chemotherapeutic agent, a radiation therapeutic agent, a hormonal therapeutic agent, or an immunotherapeutic agent.

Claim 65. **[Withdrawn Previously Presented]** A method of treating an autoimmune disorder in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an antibody that is a chimeric or humanized version of the murine monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591, or an antigen binding fragment thereof.

Claim 66. **[Withdrawn]** The method of claim 65, wherein said autoimmune disorder is rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Rieter's Syndrome, psoriasis, or lupus erythematosus.

Claim 67. **[Withdrawn]** The method of claim 65 further comprising administering to said patient a therapeutically effective amount one or more anti-inflammatory agents.

Claim 68. **[Withdrawn]** The method of claim 65 further comprising administering to said patient a therapeutically effective amount one or more immunomodulatory agents.

Claim 69. **[Withdrawn]** The method of claim 68, wherein at least one immunomodulatory agent is a small organic molecule.

Claim 70. **[Withdrawn]** The method of claim 69, wherein the small organic molecule is methotrexate, leflunomide, cyclophosphamide, cyclosporin A, FK506, mycophenolate mofetil, rapamycin, mizoribine, deoxyspergualin, brequinar, malonitrolamide, steroid, or corticosteroid.

Claim 71. **[Withdrawn]** The method of claim 67, wherein at least one anti-inflammatory agent is a non-steroidal anti-inflammatory drug.

Claim 72. **[Withdrawn]** The method of claim 71, wherein the non-steroidal anti-inflammatory drug is aspirin, ibuprofen, diclofenac, nabumetone, naproxen, or ketoproten.

Claim 73. **[Withdrawn Previously Presented]** A method for treating or preventing an IgE-mediated allergic disorder in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of an antibody that is a chimeric or humanized version

of the murine monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591, or an antigen binding fragment thereof.

Claim 74. **[Withdrawn Currently Amended]** The method of claim 73, wherein said IgE-mediated allergic disorder is asthma, allergic rhinitis, gastrointestinal allergies, eosinophilia, conjunctivitis, or ~~**golmerular**~~ **glomerular** nephritis.

Claim 75. **[Withdrawn]** The method of claims 65 or 73, wherein said patient is human.

Claim 76. **[Withdrawn]** The method of claim 75, wherein said antibody is a humanized version.

Claim 77. **[Withdrawn Previously Presented]** A method of enhancing an antibody mediated cytotoxic effect in a subject being treated with a cytotoxic antibody, said method comprising administering to said patient an antibody that is a chimeric or humanized version of the murine monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591, or an antigen binding fragment thereof in an amount sufficient to enhance the cytotoxic effect of said cytotoxic antibody.

Claim 78. **[Withdrawn Previously Presented]** A method of diagnosis of an autoimmune disease in a subject comprising: (a) contacting a biological sample from said subject with an effective amount of the antibody or fragment of claim 38; and (b) detecting binding of said antibody or fragment, wherein detection of said antibody or fragment above a background or standard level indicates that said subject has an

autoimmune disease.

Claim 79. **[Withdrawn Previously Presented]** The method of claim 78, wherein said antibody or fragment comprises a detectable marker, which detectable marker is a chemiluminescent, enzymatic, fluorescent, or radioactive label.

Claim 80. **[Withdrawn Previously Presented]** A method of enhancing an immune response to a vaccine composition in a subject, said method comprising administering to said subject an antibody that is a chimeric or humanized version of the murine monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591, or an antigen binding fragment thereof, and a vaccine composition, said antibody or fragment thereof being administered in an amount effective to enhance the immune response to said vaccine composition in said subject.

Claims 81-89. **[Cancelled]**

Claim 90. **[Previously Presented]** A pharmaceutical composition comprising (i) a therapeutically effective amount of an antibody that is a chimeric or humanized version of the murine monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591, or an antigen binding fragment thereof; and (ii) a pharmaceutically acceptable carrier.

Claims 91-92 **[Cancelled]**

Claim 93. **[Withdrawn Previously Presented]** A method of treating cancer in a patient, said method comprising administering to said patient a therapeutically effective amount of an antibody that is a chimeric or

humanized version of the murine monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591, or an antigen binding fragment thereof.

Claim 94. **[Withdrawn Previously Presented]** A method of treating a B cell malignancy in a patient, said method comprising administering to said patient a therapeutically effective amount of an antibody that is a chimeric or humanized version of the murine monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591, or an antigen binding fragment thereof.

Claim 95. **[Withdrawn]** The method of claim 94, wherein said B cell malignancy is non-Hodgkin's lymphoma.

Claim 96. **[Withdrawn Previously Presented]** A method of treating a disease in a patient comprising administering to said patient a therapeutically effective amount of a first antibody that is a chimeric or humanized version of the murine monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591, or an antigen binding fragment thereof, and a second antibody, wherein said second antibody does not mediate its therapeutic effect by cell killing.

Claim 97. **[Withdrawn]** The method of claim 96, wherein said second antibody is an anti-Fas antibody.

Claim 98. **[Withdrawn Previously Presented]** A method of treating a solid tumor in a patient having a tumor characterized by infiltration of a population of macrophages at the site of the tumor, said method comprising administering a therapeutically effective amount of a first antibody that is a chimeric or humanized version of the murine

monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591, or an antigen binding fragment thereof wherein said administration reduces the population of macrophages.

Claim 99. **[Withdrawn]** The method of claim 98 wherein said antibody reduces the population of macrophages by at least 80%.

Claim 100. **[Withdrawn Previously Presented]** A method of treating cancer in a patient having a cancer characterized by a cancer antigen, said method comprising administering to said patient a therapeutically effective amount of a first antibody that is a chimeric or humanized version of the murine monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591, or an antigen binding fragment thereof , and a second antibody that does not bind said cancer antigen.

Claim 101. **[Withdrawn]** The method of claim 100, wherein said second antibody binds a cancer antigen expressed on a cell surrounding a tumor cell.

Claim 102. **[Withdrawn]** The method of claim 101, wherein said cell is a fibroblast cell or a stromal cell.

Claim 103. **[Withdrawn]** The method of claim 102, wherein said cancer antigen is fibroblast activation protein.

Claim 104. **[Previously Presented]** The antibody of claim 41, further comprising at least one modification in the Fc region.

Claim 105. **[Previously Presented]** The antibody of claim 104, wherein said Fc region has an altered affinity for an FcγR.

Claim 106. **[Previously Presented]** The antibody of claim 104, wherein said

Fc region binds FcγRIIIA with a higher affinity than a comparable antibody comprising a wild-type Fc region binds FcγRIIIA.

Claim 107. **[Original]** The antibody of claim 104, wherein said antibody has an enhanced antibody mediated effector function relative to a comparable antibody comprising a wild-type Fc region.

Claims 108-110. **[Cancelled]**

Claim 111. **[Previously Presented]** The antibody of claim 41 which is a humanized version of 2B6 or an antigen binding fragment thereof.

Claim 112 **[Previously Presented]** The antibody of claim 41 which is a chimeric version of2B6 or an antigen binding fragment thereof.

Claim 113. **[Previously Presented]** The antibody of claim 41 which is a $F(ab')_2$ or a F(ab') fragment.

Claim 114. **[Previously Presented]** The antibody of claim 41 which is a single chain antibody.

Claim 115. **[Previously Presented]** The antibody of claim 41, wherein said antibody is operably linked to a heterologous polypeptide.

Claim 116. **[Previously Presented]** The antibody of claim 115, wherein said heterologous polypeptide is an antibody that immunospecifically binds a cell surface receptor.

Claim 117. **[Currently Amended]** The antibody of claim ~~116~~ **115**, wherein said heterologous polypeptide is an antibody that immunospecifically binds to a tumor antigen.

Claim 118. **[Previously Presented]** The antibody of claim 41, wherein said antibody is conjugated to a therapeutic agent.

Claim 119. **[Previously Presented]** The antibody of claim 118, wherein said therapeutic agent is a cytotoxin.

Claim 120. **[Currently Amended]** The antibody of claim 119, wherein said cytotoxin is paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, **a** glucocorticoid**s**, procaine, tetracaine, lidocaine, propranolol, puromycin, epirubicin, or cyclophosphamide.

Claim 121. **[Previously Presented]** The antibody of claim 41, wherein said antibody comprises at least one amino acid modification in the Fc region relative to a comparable wild-type Fc region.

Claim 122. **[Previously Presented]** The pharmaceutical composition of claim 60, wherein said first antibody is a humanized version of 2B6, or an antigen binding fragment thereof.

Claim 123. **[Previously Presented]** The pharmaceutical composition of claim 60, wherein said first antibody is a chimeric version of 2B6, or an antigen binding fragment thereof.

Claim 124. **[Previously Presented]** The pharmaceutical composition of claim 60, wherein said first antibody is a fragment, which fragment is a $F(ab')_2$ or F(ab') fragment.

Claim 125. **[Previously Presented]** The pharmaceutical composition of claim 90,

wherein said antibody is a humanized version of2B6, or an antigen binding fragment thereof.

Claim 126. **[Previously Presented]** The pharmaceutical composition of claim 90, wherein said antibody is a chimeric version of 2B6, or an antigen binding fragment thereof.

Claim 127. **[Previously Presented]** The pharmaceutical composition of claim 90, wherein said antibody is a $F(ab')_2$ or F(ab') fragment.

Claim 128. **[Previously Presented]** An isolated antibody, or antigen binding fragment thereof, comprising a light chain variable region and a heavy chain variable region from the murine monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591.

Claim 129 **[Previously Presented]** An isolated antibody, or antigen binding fragment thereof, comprising a light chain variable region from the murine monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591 wherein said antibody comprises a variable domain that specifically binds the extracellular domain of FcγRIIB with greater affinity than said variable domain binds FcγRIIA.

Claim 130 **[Previously Presented]** An isolated antibody, or antigen binding fragment thereof, comprising a heavy chain variable region from the murine monoclonal antibody produced by clone 2B6, having ATCC accession number PTA-4591 wherein said antibody comprises a variable domain that specifically binds the extracellular domain of FcγRIIB with greater affinity than said variable domain binds FcγRIIA.

Claim 131. **[Previously Presented]** The antibody of claim 129 or 130, wherein

said binding agonizes at least one activity of FcγRIIB, which activity is selected from the group consisting of B cell receptor-mediated signaling and inhibition of FcεRI-induced mast cell activation.

Claim 132. **[Previously Presented]** The antibody of claim 129 or 130 which inhibits B cell proliferation, antibody production, intracellular calcium influx, or activity of one or more downstream signaling molecules in the FcγRIIB signal transduction pathway.

Claim 133. **[Previously Presented]** The antibody of claim 129 or 130 which enhances phosphorylation of FcγRIIB and/or recruitment of one or more downstream signaling molecules in the FcγRIIB signal transduction pathway.

Claim 134. **[Previously Presented]** The antibody of claim 129 or 130, wherein said binding antagonizes at least one activity of FcγRIIB, wherein said at least one activity is selected from the group consisting of activation of B cell receptor-mediated signaling, and activation of FcεRI-induced mast cell activation.

Claim 135. **[Previously Presented]** The antibody of claim 129 or 130 which enhances B cell proliferation, antibody production, intracellular calcium influx, or activity of one or more downstream signaling molecules in the FcγRIIB signal transduction pathway.

Claim 136. **[Previously Presented]** The antibody of claim 129 or 130 which reduces phosphorylation of FcγRIIB and/or recruitment of one or more downstream signaling molecules in the FcγRIIB signal transduction pathway.

Claim 137 **[Previously Presented]** The antibody of claim 129 or 130, wherein said antibody is a monoclonal antibody.

Claim 138. **[Previously Presented]** A humanized version of the antibody of claim 129 or 130.

Claim 139 **[Previously Presented]** The antibody of claim 129 or 130, wherein said antibody is a fragment, which fragment is a $F(ab')_2$ or F(ab') fragment.

Claim 140. **[Previously Presented]** The antibody of claim 129 or 130 which blocks the binding of an Ig-Fc to FcγRIIB.